David Alexanderian is the Global Clinical Development Lead (GCDL) for the Hunter-IT and Elaprase Programs. He supports the development and execution of medical and clinical leadership strategies for these programs. In this role, David maintains oversight of study design and data generated from clinical trials. He interacts with Drug Safety, Device, Global Medical Affairs, Device, Regulatory, Commercial, and Marketing teams. Additional responsibilities include advisory panels and publication planning.
David joined Shire/Takeda in 2014, where his responsibilities included the Sanfilippo A and HIT projects. Prior to joining Shire, David held a similar position at Novartis Vaccines, Vertex Pharmaceuticals, and Tolerx. David was a Clinical Professor at NYU School of Medicine and practiced at NYU Belleview Hospital in New York City. He graduated from Dickinson College in Chemistry and went on to complete his medical degree at Des Moines University.